Navigation Links
Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
Date:11/6/2008

SAN CARLOS, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a total purchase price of $47.8 million. The company also reported its financial results for the third quarter and nine-months ended September 30, 2008.

"The turnaround at Nektar is now largely complete," said Nektar President and CEO Howard W. Robin. "We have created one of the most robust pipelines in biotech, dramatically improved the company's financial strength, assembled a new management team with a solid track record, and refocused the business around our powerful polymer and conjugate chemistry drug development platform."

Third Quarter 2008 Financial Results

Cash, cash equivalents, and short-term investments were $344.5 million at September 30, 2008 compared to $373.9 million at June 30, 2008.

Revenue for the three month period ended September 30, 2008 was $21.4 million compared to revenue of $56.3 million in the third quarter of 2007. For the first nine months of 2008, revenue was $61.8 million as compared to $207.3 million in the same period of 2007. This decrease in revenue is primarily the result of lower product manufacturing revenues due to the termination of the inhaled insulin collaboration by Pfizer in late 2007.

Nektar has continued to make significant improvements to its operating efficiencies as compared to a year ago. For the first nine months of 2008, the company's general and administrative expense was $37.0 million as compared to $42.3 million for the same period a year ago. Research and development expense was $109.1 million in the first nine months
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics Announces Second Quarter 2008 Results
3. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
4. Nektar Therapeutics Announces First Quarter 2008 Results
5. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
6. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
7. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
9. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... 2015 The Contract Research Organizations ... research, manage data results and help develop and ... regulation standards. Contract research organizations (CROs) mainly serve ... sectors. Industry operators provide clients with a full ... research for Food and Drug Administration (FDA) approval. ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 North American ... PT Online Continuing Education Courses . ... hours of CME - TPTA, approval # 56399TX      ... evaluation of the shoulder complex - 10.5 hours - ... #56400TX , Examination and Treatment of the SI Joint ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 "Necrorun" was ... which takes a look at the latest and coolest ... Joe Troohey, the host of NewsWatch and technology expert, ... this is an entertaining endless runner game with knights, ... game was released in 2009, according to Eurogamer. The ...
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 28, 2015 One in three young ... research presented today at the American Orthopaedic Society for ... examined the long term success of surgery for patients ... survey data from 242 patients who underwent ACL reconstruction ... Roe, MBBS, FRACS, from North Sydney Orthopaedic and Sports ...
Breaking Medicine News(10 mins):Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Contract Research Organizations in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2
... Jan. 3 Continuing its role as ... organizations, the,American Association of Preferred Provider Organizations ... Care Administrators Association,(HCAA) that will significantly enhance ... consolidation and increased consumerism continue to fuel,further ...
... and Hispanic ethnic groups and others with a family history of ... glaucoma are particularly vulnerable, ... have no early symptoms and do not notice as their peripheral,vision ... the,three million Americans with the disease are unaware of their condition.,January ...
... In an era of expanding competition,from generics, expiring ... in new drug discoveries, there is very little ... report by Kalorama Information entitled Drug,Pricing and Reimbursement ... companies the information they need to,reevaluate their pricing ...
... 3 RxElite, Inc. (OTC,Bulletin Board: RXEI), a ... products, announced today that a registration,statement covering the ... effective by the Securities and Exchange Commission on ... informational purposes only, and does not,represent a solicitation ...
... finds one-hour session produces as much carbon monoxide as a ... A leisurely hour of puffs from a hookah -- a ... -- packs the same carbon monoxide punch as a pack-a-day ... looks at a single toxic gas, making it impossible to ...
... Emory University have developed a novel anti-tumor compound that represents ... points" for cancer cells. , The results of research on ... of Cancer Research. The article is highlighted on the cover. ... human patients with solid tumors in 2007. , The idea ...
Cached Medicine News:Health News:AAPPO and HCAA Form Partnership to Enhance Services to Meet the Changing Business Needs of PPOs and TPAs 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 2Health News:Knowing Your Risks Can Stop the Sneak Thief of Sight 3Health News:Generic Onslaught Makes Drug Pricing Decisions More Critical Than Ever 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 2Health News:Hookah Smoking as Tough on Lungs as Cigarettes 3Health News:Novel anticancer strategy moves from laboratory to clinic 2Health News:Novel anticancer strategy moves from laboratory to clinic 3
(Date:3/27/2015)... 27, 2015 The Temple Health & Bioscience District ... 5,000-square-foot building at 1802 South First St. in the Temple ... the City of Temple to receive ... the Central Texas Veterans Health Care System, the new facility ... early stage biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
(Date:3/27/2015)... LAS VEGAS , March 27, 2015 Zimmer ... more efficient external fixation system for trauma patients. ... the XtraFix ® External Fixation System from ... design technology and materials.   The XtraFix ... and clamps from the external fixation process, resulting in saved ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3
... Transdermal System CIII 20 mcg/hour provided significantly ... compared to Butrans 5 mcg/hour when used in opioid-experienced ... according to a pivotal Phase 3 clinical study published ... of Pain . (Logo: http://photos.prnewswire.com/prnh/20100921/NY67262) ...
... SILVER SPRING, Md., Sept. 23, 2011 The U.S. ... treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a ... kidney (renal) failure and is also associated with increased ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Atypical HUS accounts ...
Cached Medicine Technology:Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 2Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 3Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 4Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 5Results of a Pivotal Phase 3 Efficacy and Safety Study for Butrans® (Buprenorphine) Transdermal System CIII Published in The Journal of Pain 6FDA Approves Soliris for Rare Pediatric Blood Disorder 2FDA Approves Soliris for Rare Pediatric Blood Disorder 3
... EVLT, the #1 physician choice in ... advantages to remedying superficial vein reflux. EVLT ... to surgical vein stripping that effectively and ... laser fiber to occlude the vein. The ...
... Aculens 186 UV combines the latest technology ... measurement of ultra violet transmission and auto ... is also programmed to network with the ... Instruments, today, or in the future. , ...
Inquire...
...
Medicine Products: